Spectra254 announces the formation of its company dedicated to the production and sale of mobile UV-C light sanitation systems designed to eliminate 99.9 percent of pathogens in the air and on surfaces.
Spectra254 is a privately held, fully-funded enterprise with decades of experience in research and new product development within the fast-growing technology arena. Its UVC light sanitation systems are designed for use by hospitals and healthcare facilities, markets where a rise in incidences of healthcare-associated infections - impacting nearly one in every 25 hospital patients, according to the Centers for Disease Control and Prevention (CDC) - has spurred the demand for products that kill germs on surfaces and in the air with ultraviolet light. Other applications with a need to sterilize an area and kill surface and air pathogens include assisted living facilities, sports programs, hospitality and the education market.
“At Spectra254 we are committed to developing products based on the effectiveness of UVC light in eradicating pathogens and ensuring healthier and safer environments,” said Sanford Green, president of Spectra254. “We fully embrace the need to invest in new ideas that will achieve long-term results using the most reliable, effective, cost-efficient means possible.”
Spectra254 key executives include founder, CEO and long-time entrepreneur George J. Lichtblau. Lichtblau holds more than 20 U.S. patents, many of them related to optic technology from two other companies he founded - International Fiber Systems and ComNet, both of which serve the data transmission market.
Spectra254’s flagship product, the Spectra 1000, is a portable, high-power ultraviolet light-generating device, ideal for hospital operating rooms and patient rooms, health-care facilities, locker rooms and other areas where contamination is of critical concern.
Its eight high-intensity, custom-made lamps broadcast UVC light to virtually every surface in the treated area, killing the pathogens. Easy-to-use and affordable, the Spectra 1000 has the capability to eradicate 99.98 percent of pathogens with 5 minutes of use at 15 feet, providing a “green” alternative to the typical use of harsh chemicals.
Within the next few months, Spectra254 will release its second-generation product, the Spectra 1100. Independent analysis performed for Spectra254 by EMSL Analytical Inc. showed that the UVC light generated by the Spectra 1100 system was highly effective (greater than 99.9 percent) at killing virulent pathogens such as MRSA and C. difficile spores on solid surfaces and inhibiting the growth over a range of exposure times and distances.
The company’s systems are manufactured and assembled in a U.S.-based ISO 9000 facility that meets or exceeds the quality assurance standards outlined by International Organization of Standards.
Source: Spectra254
Show, Tell, Teach: Elevating EVS Training Through Cognitive Science and Performance Coaching
April 25th 2025Training EVS workers for hygiene excellence demands more than manuals—it requires active engagement, motor skills coaching, and teach-back techniques to reduce HAIs and improve patient outcomes.
The Rise of Disposable Products in Health Care Cleaning and Linens
April 25th 2025Health care-associated infections are driving a shift toward disposable microfiber cloths, mop pads, and curtains—offering infection prevention, regulatory compliance, and operational efficiency in one-time-use solutions.
Vet IP Roundtable 2: Infection Control and Biosecurity Challenges in Veterinary Care
March 31st 2025Veterinary IPs highlight critical gaps in cleaning protocols, training, and biosecurity, stressing the urgent need for standardized, animal-specific infection prevention practices across diverse care settings.
Invisible, Indispensable: The Vital Role of AHRQ in Infection Prevention
March 25th 2025With health care systems under strain and infection preventionists being laid off nationwide, a little-known federal agency stands as a last line of defense against preventable patient harm. Yet the Agency for Healthcare Research and Quality (AHRQ) is now facing devastating cuts—threatening decades of progress in patient safety.